Table 3 Number of CRC by detection modes and model validity with the overdiagnosis-embedded disease natural history model of two gFOBT randomized controlled trials of CRC screening.
Parameter | Status | Nottingham trial (UK) | Funen trial (Demark) | ||
|---|---|---|---|---|---|
Screening finding by round | Observed | Predicted | Observed | Predicted | |
Prevalent screening | Normal | 44733 | 44735.42 | 20635 | 20630.24 |
| Â | CRC | 104 | 101.58 | 37 | 41.76 |
Interval cancer | CRC | 164 | 140.04 | 148 | 147.23 |
Positive but without confirmation (first round) | CRC | 28 | 27.76 | ---- | ---- |
Positive but without confirmation (repeated round) | CRC | 57 | 66.03 | ---- | ---- |
Repeated screening | Normal | 88008 | 87977.51 | 66025 | 66014.12 |
| Â | CRC | 132 | 109.69 | 83 | 67.74 |
Refuser | Normal | 30015 | 30014.06 | 9895 | 9895.71 |
| Â | CRC | 400 | 400.94 | 195 | 194.29 |
Internal validity Goodness of fit: Chi-square | Â | 9.9421 (d.f.=6) | 3.9895 (d.f.=4) | ||
| Â | (p value = 0.1271) | (p value = 0.4074) | |||
